Categories: News

Britannia Life Sciences Inc. Announces Results of Annual Meeting of Shareholders

Toronto, Ontario–(Newsfile Corp. – November 14, 2024) – Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company“) is pleased to announce the results of its annual general and special meeting of shareholders held on November 12, 2024, in Toronto (the “Meeting“).

All matters presented for approval at the Meeting were duly authorized and approved, as follows:

  1. Electing each of Scott Secord, Peter Shippen and Greg Taylor as directors of the Company to hold office for the ensuing year;
  2. Re-appointing Zeifmans LLP as the auditor of the Company until the next annual meeting of shareholders and authorizing the board of directors to fix their remuneration; and
  3. Re-approving the Company’s omnibus equity compensation plan.

About Britannia Life Sciences Inc.

Britannia Life Sciences Inc. is focused on introducing cutting-edge technologies into the traditional laboratory and regulatory platforms to power data-driven insights to improve the outcomes of its customers. Britannia’s services, including product formulations, safety assessments, analytical and microbiological testing, global compliance, and consumer evaluations are offered to companies ranging from multinationals to startups particularly in the cosmetics, food, and wellness industries. Britannia also provides geochemical testing and analysis to the natural resources industry through its subsidiary Britannia Mining Solutions. Britannia Mining Solutions operates a geochemical laboratory in the United States and is in the process of rolling out 12 PhotonAssayTM machines globally, the first two of which have been installed and commissioned to-date.

Britannia’s head office is located at 120 Adelaide Street West, Suite 2400, Toronto, Ontario, M5H 1T1.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229946

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

2 hours ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

2 hours ago